# Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I

Source: [science.org](https://www.science.org/doi/abs/10.1126/scitranslmed.aei9706?af=R) · 2026-11-18 · Medicine
Page: https://themorning.science/story/oligonucleotide-mediated-aass-silencing-as-a-potential-therapeutic-strategy-for-f5100ad4d089ce47
Kind: research · Impact: low

## In brief

- A research article in Science Translational Medicine (November 2026) proposes silencing the AASS gene with oligonucleotides as a potential therapy.
- The strategy is aimed at ALDH7A1 deficiency and glutaric aciduria type I.
- The source is the article title and bibliographic details only; the study's results are not described in the provided material.

## Why it matters

It proposes a gene-silencing approach for a rare inherited metabolic disorder, which could inform future therapy development for glutaric aciduria type I and ALDH7A1 deficiency.

## Timeline

- 2026-11-18: Article published in Science Translational Medicine

## Coverage

- [Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I](https://www.science.org/doi/abs/10.1126/scitranslmed.aei9706?af=R) — science.org, 2026-11-18

Tags: glutaric aciduria type i, aldh7a1 deficiency, aass, oligonucleotide therapy, inborn errors of metabolism

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
